Fig. 3
From: Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer
Effect of combination therapies on primary tumor growth in the Y537S ERα mutant model. a Total photon flux of luminescence signals measured by in vivo imaging over time for different dose combinations of lasofoxifene and palbociclib. b Tumor weight at sacrifice (n = 5–6). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by one-way ANOVA. Additional p-values not shown: p < 0.05 for vehicle vs fulvestrant; p < 0.0001 for vehicle vs every other treatment; p < 0.01 for fulvestrant vs palbociclib 35 mg/kg; p < 0.0001 for fulvestrant vs every other treatment. F, fulvestrant; L5 and L10, lasofoxifene at 5 and 10 mg/kg; P35 and P70, palbociclib at 35 and 70 mg/kg; SEM, standard error of the mean; V, vehicle